Volume 56, Issue 1, Pages (July 1999)

Slides:



Advertisements
Similar presentations
Volume 66, Issue 4, Pages (October 2004)
Advertisements

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Volume 65, Issue 2, Pages (February 2004)
Persistent secondary hyperparathyroidism after renal transplantation
E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P
Volume 73, Issue 1, Pages 3-5 (January 2008)
Linear and logistic regression analysis
Elaine M. Spalding, Paul W. Chamney, Ken Farrington 
Volume 78, Pages S10-S21 (August 2010)
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Volume 76, Pages S50-S99 (August 2009)
Volume 70, Pages S12-S15 (July 2006)
Prediction of hypertension in chronic hemodialysis patients
Percentage of Hepatitis C Virus-Infected Hepatocytes Is a Better Predictor of Response Than Serum Viremia Levels  Elena Rodríguez-Iñigo, Juan Manuel López-Alcorocho,
Graphic Interpretation of Serum Parathyroid Hormone, Calcium, and Phosphorus Values in Primary Hyperparathyroidism  Pai C. Kao, Ph.D., Edward G. Lufkin,
A new era in phosphate binder therapy: What are the options?
The need for reliable serum parathyroid hormone measurements
Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1α-hydroxylase  Mutsuko Ohnishi, Teruyo.
Use of vitamin D in chronic kidney disease patients
G. Tripepi, K.J. Jager, F.W. Dekker, C. Wanner, C. Zoccali 
Volume 87, Issue 2, Pages (February 2015)
Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.
Volume 67, Pages S33-S36 (June 2005)
Bradley A. Ford, Daniel W. Coyne, Charles S. Eby, Mitchell G. Scott 
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
Ewa Lewin, Yolanda Almaden, Mariano Rodriguez, Klaus Olgaard 
Volume 90, Issue 6, Pages (December 2016)
Prescribing and monitoring hemodialysis dose
Volume 63, Pages S115-S118 (June 2003)
Persistent secondary hyperparathyroidism after renal transplantation
Volume 65, Issue 5, Pages (May 2004)
Structure, not just function
Volume 56, Pages S31-S37 (December 1999)
Volume 56, Issue 2, Pages (August 1999)
Volume 55, Issue 4, Pages (April 1999)
Volume 87, Issue 3, Pages (March 2015)
Volume 68, Issue 3, Pages (September 2005)
Volume 71, Issue 6, Pages (March 2007)
Volume 55, Issue 4, Pages (April 1999)
Pathogenesis of refractory secondary hyperparathyroidism
Keng-Thye Woo, Yeow-Kok Lau, Kok-Seng Wong, Gilbert Shih-Chen Chiang 
Volume 67, Issue 3, Pages (March 2005)
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients
A man with a hole in his penis
Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita  Kidney International 
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients  B. Bammens, P. Evenepoel, H. Keuleers,
Volume 56, Issue 4, Pages (October 1999)
Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study1  Robert N. Foley, Charles A. Herzog, Allan J.
Volume 63, Pages S79-S82 (June 2003)
Volume 63, Issue 2, Pages (February 2003)
Volume 64, Issue 6, Pages (December 2003)
Pablo A. Ureña Torres, Marc De Broe  Kidney International 
Volume 58, Issue 3, Pages (September 2000)
Volume 57, Issue 3, Pages (March 2000)
Volume 64, Issue 1, Pages (July 2003)
Recent developments in the management of secondary hyperparathyroidism
Volume 75, Issue 9, Pages (May 2009)
MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis  Antonio Guasch, M.D., Carlos F. Zayas, Kamal.
Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease  Aquiles Jara, Arnold J. Felsenfeld, Jordi.
Volume 54, Issue 6, Pages (January 1998)
Evaluation of the Losartan in Hemodialysis (ELHE) Study
Increased fetuin-A levels following treatment with a vitamin D analog
The ins and outs of phosphate homeostasis
Volume 66, Issue 4, Pages (October 2004)
PTH response to the predialysis serum calcium concentration in hemodialysis patients with severe (A), moderate (B), and mild (C) hyperparathyroidism. PTH.
Volume 61, Issue 4, Pages (April 2002)
Volume 55, Issue 5, Pages (May 1999)
A novel mechanism for skeletal resistance in uremia
Volume 82, Issue 1, Pages (July 2012)
Volume 64, Pages S131-S136 (November 2003)
Presentation transcript:

Volume 56, Issue 1, Pages 306-317 (July 1999) Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient  Mariano Rodriguez, Dr, Francisco Caravaca, Elvira Fernandez, Maria J. Borrego, Victor Lorenzo, Juan Cubero, Alejandro Martin-Malo, Angels Betriu, Alejandro Jimenez, Armando Torres, Arnold J. Felsenfeld  Kidney International  Volume 56, Issue 1, Pages 306-317 (July 1999) DOI: 10.1046/j.1523-1755.1999.00538.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Logistic regression model to predict response to calcitriol treatment. Stepwise logistic regression analysis showed that the precalcitriol basal parathyroid hormone (PTH) level was the most important predictor of the probability of a 40% reduction in basal PTH during calcitriol treatment. Using the previously mentioned model, a 50% probability of a response (40% reduction in basal PTH) was observed at a precalcitriol basal PTH value of 750 pg/ml. At a basal PTH of 1200 pg/ml, the probability of a response to calcitriol was less than 20%, and at a basal PTH of 400 pg/ml, the probability of a response approached 80%. Kidney International 1999 56, 306-317DOI: (10.1046/j.1523-1755.1999.00538.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Parathyroid function before calcitriol treatment in responders and nonresponders. The original group of 50 patients was divided into responders and nonresponders based on whether a 40% reduction in the basal PTH was observed with calcitriol treatment. Shown in the left panel are the correlations before calcitriol treatment in the responders (N = 25) between serum calcium and basal PTH, maximal PTH, the basal/maximal PTH ratio, and minimal PTH. Shown in the right panel are the correlations before calcitriol treatment in the nonresponders (N = 25) between serum calcium and basal PTH, maximal PTH, the basal/maximal PTH ratio, and minimal PTH. Kidney International 1999 56, 306-317DOI: (10.1046/j.1523-1755.1999.00538.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 Patterns of PTH secretion in responders and nonresponders. The mean basal/maximal PTH ratio (×100) is shown before (▪) and after (○) calcitriol treatment in (A and B) and the absolute changes in basal and maximal PTH are shown in (C and D). Symbols in C and D are: (solid line) pre-CTR; (dashed line) post-CTR; (▵) PTHmax; (○) basal PTH; (□) PTHmin. Before calcitriol treatment, the mean basal/maximal PTH ratio was similar in the responders (A; P < 0.001 pre- vs. post-CTR) and nonresponders (B). In both groups, a similar shift to the right of the PTH-calcium curve shifted was observed during calcitriol treatment with sustained increases in the serum calcium concentration. However, in only the responders was the rightward shift in the PTH-calcium curve associated with a decrease in the mean basal/maximal PTH ratio. In (C and D), the absolute values for basal, maximal, and minimal PTH are shown. Before calcitriol treatment, the basal and maximal PTH levels were less in the responders (C) than the nonresponders (D), and minimal PTH was not different. With calcitriol treatment, basal, maximal, and minimal PTH values decreased in the responders (C), but were essentially unchanged in the nonresponders (D). Kidney International 1999 56, 306-317DOI: (10.1046/j.1523-1755.1999.00538.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 4 Parathyroid function after calcitriol treatment in responders and nonresponders. The original group of 50 patients was divided into responders and nonresponders based on whether a 40% reduction in the basal PTH was observed with calcitriol treatment. Shown in the left panel are the correlations after calcitriol treatment in the responders (N = 25) between serum calcium and basal PTH, maximal PTH, the basal/maximal PTH ratio, and minimal PTH. Shown in the right panel are the correlations after calcitriol treatment in the nonresponders (N = 25) between serum calcium and basal PTH, maximal PTH, the basal/maximal PTH ratio, and minimal PTH. Symbols are: (solid line) pre-CTR; (dashed line) post-CTR; (dotted line in A) basal PTH; (dotted line in B) basal/maximum PTH. Kidney International 1999 56, 306-317DOI: (10.1046/j.1523-1755.1999.00538.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 5 Schematic representation of changes in parathyroid function before and after calcitriol treatment in responders. A schematic representation of the changes in the PTH-calcium curve is shown before (solid line) and after (dashed line) calcitriol treatment in the responder group with PTH in (A) in absolute values and (B) as a percentage of maximal PTH. The figure is drawn to show that in both (A and B), the PTH-calcium curve moves both vertically at various serum calcium concentrations in the classic sigmoidal PTH in response to acute changes in serum calcium and horizontally in the direction of sustained changes in the serum calcium. As shown in (A), as the serum calcium increased before calcitriol treatment, basal PTH remained constant even though maximal PTH increased, and as a result, (B) the basal/maximal PTH ratio decreased as the serum calcium increased. After calcitriol treatment (A), both basal and maximal PTH markedly decreased markedly in absolute values, and serum calcium increased from precalcitriol levels. Despite these marked reductions in basal and maximal PTH, basal PTH values remained constant over a wide range of serum calcium values. However, as shown in (B), an inverse correlation was present between calcium and the basal/maximal PTH, and more remarkably, despite the marked differences in basal and maximal PTH before and after calcitriol treatment, the precalcitriol and postcalcitriol correlation between calcium and basal/maximal PTH appeared to be a continuum. Kidney International 1999 56, 306-317DOI: (10.1046/j.1523-1755.1999.00538.x) Copyright © 1999 International Society of Nephrology Terms and Conditions